NewGenIvf Group Limited
- Open
- 1.22
- Day high
- 1.25
- Day low
- 1.18
- Prev close
- 1.21
- Volume
- 14K
- Mkt cap
- $3M
- P/E (TTM)
- 0.0
- EPS (TTM)
- $85.47
- P/B
- 0.1
- P/S
- 0.5
- Yield
- —
- Per share
- —
- ▲Insiders net buying $3.4M over the last 3 months (3 open-market buys, 1 sale)
- 🏛Institutions mixed (13F)
NewGenIvf Group Limited (NIVF) is a Healthcare company listed on NASDAQ. The stock is down 100% over the past year. Over the trailing 3 months, insiders filed 3 open-market buys and 1 sale (SEC Form 4).
NewGenIvf Group Limited (NIVF) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NIVF earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Sep 2, 2026 | $18.18 | $18.18 | +0.0% | $20M | +0.0% |
| Jun 30, 2026 | $556.20 | $-6.06 | -101.1% | $3M | -5.8% |
| Oct 9, 2025 | — | $12.65 | — | $2M | — |
| Sep 30, 2025 | — | $147.77 | — | $1M | — |
| Sep 29, 2024 | — | $-0.39 | — | $1M | — |
| Dec 30, 2023 | — | $-18.82 | — | $2M | — |
| May 30, 2021 | — | $-0.04 | — | — | — |
NIVF insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 2, 2026 | Cheung Kong Yiudirector, 10 percent owner: | Buy | 222,223 | $1.50 |
| Sep 2, 2026 | Cheung Kong Yiudirector, 10 percent owner: | Buy | 2,500,000 | $1.00 |
| Sep 2, 2026 | Cheung Kong Yiudirector, 10 percent owner: | Buy | 500,000 | $1.33 |
| Aug 18, 2026 | Siu Wing Fung Alfreddirector, officer: Chairman & CEO | Grant | 272,140 | $0.00 |
| Aug 18, 2026 | Fong Hei Yue Tinadirector, officer: Chief Marketing Officer | Grant | 272,140 | $0.00 |
| Jul 9, 2026 | Fong Hei Yue Tinadirector | Grant | 73,647 | $0.00 |
| Jul 9, 2026 | Siu Wing Fung Alfreddirector | Grant | 73,647 | $0.00 |
| Jun 8, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 64,945 | $0.78 |
| Jun 5, 2026 | Fong Hei Yue Tinadirector | Option | 56,851 | $0.00 |
| Jun 5, 2026 | Siu Wing Fung Alfreddirector | Option | 56,851 | $0.00 |
| Jun 4, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 23,018 | $0.94 |
| Jun 4, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 11,738 | $0.88 |
| May 28, 2026 | HRT FINANCIAL LP10 percent owner | Sell | 85,317 | $0.80 |
| May 27, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 27,993 | $0.92 |
| May 27, 2026 | HRT FINANCIAL LP10 percent owner | Buy | 137,541 | $0.99 |
Source: NIVF SEC Form 4 filings, latest Sep 2, 2026. For informational purposes only — not investment advice.
See the full NIVF insider & 13F page →NewGenIvf Group Limited company profile
Overview
NewGenIVF Group Limited (NASDAQ:NIVF) is a Thailand-based assisted reproductive services provider that went public in March 2022. Founded to address the growing demand for fertility treatments in Southeast Asia, the company operates fertility clinics primarily in Thailand and has expanded its services to help couples and individuals build families through advanced reproductive technologies. Since its IPO, the company has faced significant operational and financial challenges while attempting to establish itself in the competitive fertility treatment market.
Business
NewGenIVF operates in the assisted reproductive technology (ART) industry, which encompasses medical procedures designed to help individuals and couples conceive children when natural conception is difficult or impossible. The company's core business revolves around in-vitro fertilization (IVF) treatments, a process where eggs are retrieved from a woman's ovaries and fertilized with sperm in a laboratory setting, with the resulting embryos then transferred back to the uterus. The company offers several key services within the fertility treatment spectrum. Traditional IVF represents their primary service, involving the standard process of egg retrieval, laboratory fertilization, and embryo transfer. Egg donation services cater to women who cannot use their own eggs due to age, genetic factors, or medical conditions, utilizing donated eggs from younger, healthy donors. The company also provides surrogacy services, where another woman carries and delivers a baby for intended parents who cannot carry a pregnancy themselves. Beyond these core reproductive services, NewGenIVF offers ancillary caring services that support patients throughout their fertility journey. These typically include pre-treatment consultations, psychological counseling, nutritional guidance, and post-treatment care. The fertility treatment industry has experienced significant growth due to factors such as delayed childbearing, increasing infertility rates, and growing social acceptance of assisted reproduction technologies.
Revenue model
NewGenIVF generates revenue primarily through direct patient payments for fertility treatments and related services. Patients typically pay substantial fees for each IVF cycle, which can range from several thousand to tens of thousands of dollars depending on the complexity of treatment and local market conditions. The company's revenue model is based on fee-for-service arrangements where patients pay for individual procedures, consultations, and treatments. The customer base consists of individuals and couples seeking fertility treatments, including those with medical infertility issues, same-sex couples, and single individuals choosing to have children through assisted reproduction. Many patients require multiple treatment cycles, creating potential for recurring revenue from the same customers. Several factors significantly impact the company's margins and profitability. Regulatory changes in healthcare and fertility treatment laws can affect operational costs and service availability. Competition from established fertility clinics and hospital-based reproductive medicine departments puts pressure on pricing. Equipment and technology costs for maintaining state-of-the-art laboratory facilities and medical equipment represent substantial fixed expenses. Staffing costs for specialized reproductive endocrinologists, embryologists, and support staff are typically high due to the specialized nature of the field. Success rates directly impact patient satisfaction and referrals, making clinical outcomes crucial for long-term revenue generation. Economic downturns can reduce demand as fertility treatments are often considered elective procedures that patients may delay during financial uncertainty.
Competitive moat
NewGenIVF's competitive moat appears to be relatively weak in the current market environment. The fertility treatment industry typically relies on several potential moats including specialized medical expertise, established patient relationships, regulatory barriers, and geographic positioning. However, the company's financial performance suggests these advantages have not translated into sustainable competitive advantages. Medical expertise and reputation represent the most significant potential moat for fertility clinics, as patients often choose providers based on success rates and physician credentials. However, NewGenIVF's recent operational challenges and financial losses indicate difficulties in establishing this reputation-based advantage. Geographic positioning in Thailand could provide some protection in the local market, but the fertility treatment industry faces increasing competition from both local and international providers. The company faces substantial competitive threats from established hospital systems that can offer fertility services as part of comprehensive healthcare offerings, often with better financial resources and established patient bases. International fertility tourism creates additional competitive pressure, as patients may travel to other countries for more affordable or advanced treatments. Technological disruption in reproductive medicine, including advances in genetic screening and fertility preservation, could disadvantage smaller players who cannot invest in cutting-edge equipment and research. The regulatory environment for fertility treatments can change rapidly, potentially creating new barriers or opportunities that could benefit larger, more established competitors with greater regulatory compliance capabilities.
Risks & safety
NewGenIVF presents significant financial risk with very limited margin of safety for investors. • Cash burn and liquidity crisis: Operating cash flow of -$8.3 million in 2024 with only $458,000 in cash, indicating severe liquidity constraints and potential solvency risk within months without additional funding • Debt burden: Total liabilities of $5.1 million exceed total assets of $3.6 million, resulting in negative shareholder equity and a debt-to-equity ratio indicating financial distress • Valuation metrics: Negative price-to-book ratio of -4.4x and negative price-to-earnings ratio of -8.8x reflect the company's negative equity position and losses • Operational performance: Net loss of $474,000 in 2024 despite revenue of $5.4 million, with minimal EBITDA of $24,000 indicating poor operational efficiency • Working capital: Current ratio of 1.17x provides minimal cushion for meeting short-term obligations, with current assets barely exceeding current liabilities
Recent development
Based on the available financial data, NewGenIVF has experienced significant operational turbulence since its 2022 IPO. The company generated substantial revenue of approximately $5.4-5.9 million annually in both 2022 and 2024, indicating it has maintained its core fertility treatment operations despite financial challenges. However, the company's financial trajectory shows concerning patterns. After reporting positive net income of $501,000 in 2022, the company swung to losses, with 2024 showing a net loss of $474,000. The most alarming development has been the severe deterioration in cash flow, with operating cash flow declining from -$527,000 in 2022 to -$8.3 million in 2024. The company's balance sheet has also weakened significantly, transitioning from a relatively healthy financial position in 2022 with positive shareholder equity to negative equity by 2024. Cash reserves have dwindled dramatically from healthier levels to just $458,000 by the end of 2024, creating immediate liquidity concerns. These developments suggest the company has struggled to achieve operational efficiency and profitability in the competitive fertility treatment market, despite maintaining revenue levels. The dramatic increase in cash burn indicates either significant operational expansion that has not yet generated returns, or fundamental operational challenges in the business model.
NIVF company profile · for informational purposes only — not investment advice.
Track NIVF with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free